John Delyani
Chief Business Officer Repertoire Immune Medicines
John Delyani is Chief Business Officer at Repertoire Immune Medicines, where he leads corporate and business development strategy and execution. He brings more than 20 years of experience across biotechnology and pharmaceutical companies, having held leadership roles at Tmunity Therapeutics, Merck, and Novartis, where he guided search and evaluation, licensing strategy, and complex transactions. John has executed over 40 strategic agreements across industry and academia and holds a PhD in Physiology and an MBA.
Seminars
Thursday 10th September 2026
From Platform Potential to Deal Reality: Aligning Modality, Targets & Evidence
12:00 pm
- Integrating pan-cancer or broadly applicable targets while maintaining specificity, and using this to evidence a scalable, differentiated discovery engine without compromising safety
- How do we determine which targets align with a given modality’s safety, selectivity and therapeutic potential?
- Sharing experience demonstrating the validation of a credible platform, including evolution from platform narrative to an asset-led story
- Discussing types of deals possible for platforms versus assets, and what is the minimum evidence needed for a deal?
